Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital

Author:

Soto AlonsoORCID,Quiñones-Laveriano Dante M.ORCID,Azañero JohanORCID,Chumpitaz RafaelORCID,Claros José,Salazar Lucia,Rosales Oscar,Nuñez LizORCID,Roca David,Alcantara Andres

Abstract

Objectives To determine the risk factors for in-hospital mortality in patients with COVID-19 from a Peruvian national hospital. Methods Retrospective cohort study of medical records of patients with COVID-19 hospitalized at Hospital Nacional Hipólito Unanue (HNHU) during the months of April to August 2020. The dependent variable was in-hospital mortality. Independent variables included sociodemographic and clinical characteristics, physical examination findings, oxygen saturation (SaO2) at admission, treatment received during hospitalization and laboratory results at admission. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors. Results We included 1418 patients. Median age was 58 years (IQR 47–68 years) and 944 (66.6%) were male. The median length of hospitalization was 7 (4–13) days, and the mortality rate was 46%. The most frequent comorbidities were type 2 diabetes mellitus, hypertension, and obesity. In the adjusted analysis, mortality was associated with age (HR 1.02; 95%CI 1.02–1.03), history of surgery (HR 1.89; 95%CI 1.31–2.74), lower oxygen saturation at admission (HR 4.08; CI95% 2.72–8.05 for SaO2<70% compared to SaO2>94%), the presence of poor general condition (HR 1.81; 95% CI 1.29–2.53), altered state of consciousness (HR 1.58; 95%CI 1.18–2.11) and leukocyte levels (HR 1.01; 95%CI 1.00–1. 02). Treatment with ivermectin (HR 1.44; 95%CI 1.18–1.76) and azithromycin (HR 1.25; 95%CI 1.03–1.52) were associated with higher mortality. Treatment with corticosteroids at low to moderate doses was associated with lower mortality (HR 0.56 95%CI 0. 37–0. 86) in comparison to no steroid use. Conclusion A high mortality was found in our cohort. Low oxygen saturation at admission, age, and the presence of hematological and biochemical alterations were associated with higher mortality. The use of hydroxychloroquine, ivermectin or azithromycin was not useful and was probably associated with unfavorable outcomes. The use of corticosteroids at moderate doses was associated with lower mortality.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Impact of COVID-19 on access to healthcare in low- and middle-income countries: Current evidence and future recommendations.;M Okereke;Int J Health Plann Manage,2021

2. The impact of COVID-19 in the healthcare workforce in Peru.;J Neyra-León;J Public Health Policy,2021

3. World Health Organization. Weekly epidemiological update on COVID-19–28 December 2021 [Internet]. Emergency Situational Updates. [Accessed 10 January 2022] Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—28-december-2021#:~:text=Weekly%20epidemiological%20update%20on%20COVID%2D19%20%2D%2028%20December%202021,-Edition%2072&text=This%20corresponds%20to%20just%20under,Omicron%20variant%20is%20also%20provided.

4. Ministerio de Salud. Minsa: Casos confirmados por coronavirus COVID-19 ascienden a 1 804 915 en el Perú (Comunicado N°510) [Internet]. Noticias. 2021. [Accessed 10 January 2022]. Available from: https://www.gob.pe/institucion/minsa/noticias/490477-minsa-casos-confirmados-por-coronavirus-covid-19-ascienden-a-1-804-915-en-el-peru-comunicado-n-510

5. Diabetes mellitus e hipertensión arterial como factor de riesgo de mortalidad en pacientes con Covid-19.;PJ Navarrete-Mejía;Rev Cuerpo Méd Hosp Nac Almanzor Aguinaga Asenjo.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3